IE
LENZ

Israel Englander’s LENZ Therapeutics LENZ Stock Holding History

Israel Englander’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.57M Buy
1,508,478
+639,221
+74% +$5.15M ﹤0.01% 2446
2026
Q1 		$7.95M Buy
869,257
+329,909
+61% +$4.63M ﹤0.01% 2410
2025
Q4 		$8.63M Buy
+539,348
New +$15.7M ﹤0.01% 2419
2024
Q1 		– Sell
-12,938
Closed -$237K – 6738
2023
Q4 		$237K Sell
12,938
-716
-5% -$11.8K ﹤0.01% 5087
2023
Q3 		$237K Buy
13,654
+8,465
+163% +$147K ﹤0.01% 5032
2023
Q2 		$94.4K Sell
5,189
-5,273
-50% -$105K ﹤0.01% 5338
2023
Q1 		$179K Sell
10,462
-8,587
-45% -$139K ﹤0.01% 5218
2022
Q4 		$443K Sell
19,049
-31,047
-62% -$720K ﹤0.01% 4832
2022
Q3 		$1.11M Sell
50,096
-25,083
-33% -$598K ﹤0.01% 4246
2022
Q2 		$1.45M Buy
75,179
+57,495
+325% +$1.28M ﹤0.01% 4022
2022
Q1 		$631K Sell
17,684
-417
-2% -$26.1K ﹤0.01% 4933
2021
Q4 		$1.57M Sell
18,101
-59,206
-77% -$4.91M ﹤0.01% 3986
2021
Q3 		$8.87M Sell
77,307
-6,955
-8% -$1.03M 0.01% 2228
2021
Q2 		$18.1M Buy
+84,262
New +$14.7M 0.01% 1287

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Israel Englander's LENZ Position: Q2 2026 in Review

Israel Englander increased its LENZ Therapeutics (LENZ) stake by 74% in Q2 2026, buying an estimated $5.15M and bringing the position to 1,508,478 shares worth $8.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Israel Englander first reported a position in LENZ in Q2 2021 and has held it in 14 quarters since. The position peaked at $18.1M in Q2 2021. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Israel Englander held 1,508,478 shares of LENZ Therapeutics worth $8.57M as of Q2 2026.
  • Israel Englander bought 639,221 LENZ Therapeutics shares in Q2 2026, an estimated $5.15M.
  • LENZ Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2446 holding.
  • Israel Englander first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Israel Englander's LENZ Therapeutics position peaked at $18.1M in Q2 2021.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.